| GO ID | Ontology | GO Term | Term Definition |
Proteins |
GO:0001828 | BP | inner cell mass cellular morphogenesis | The morphogenesis of cells in the inner cell mass. |
LATS1, SOX17, LATS2 |
GO:0001829 | BP | trophectodermal cell differentiation | The process in which a relatively unspecialized cell acquires the specialized features of a trophectoderm cell. |
CNOT3, ADA, JUNB, SP3, HOPX |
GO:0001831 | BP | trophectodermal cellular morphogenesis | The morphogenesis of trophectoderm cells. |
CUL3 |
GO:0001832 | BP | blastocyst growth | An increase in size of a blastocyst due to expansion of the blastocoelic cavity cell shape changes and cell proliferation. |
NBN, RTF1 |
GO:0001833 | BP | inner cell mass cell proliferation | The proliferation of cells in the inner cell mass. |
ZPR1, BRCA2, GINS1, NCAPG2, GINS4, NDEL1, PRPF19, SBDS |
GO:0001834 | BP | trophectodermal cell proliferation | The proliferation of cells in the trophectoderm. |
ZPR1 |
GO:0001836 | BP | release of cytochrome c from mitochondria | The process that results in the movement of cytochrome c from the mitochondrial intermembrane space into the cytosol, which is part of the apoptotic signaling pathway and leads to caspase activation. |
SOD2, JUN, CCK, BCL2, CLU, SFN, BID, BAX, PMAIP1, TIMM50, BAD, MFF, BOK |
GO:0001837 | BP | epithelial to mesenchymal transition | A transition where an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. |
SNAI2, TGFB1, BMP2, HGF, FGFR2, S100A4, CTNNB1, TGFBR1, WNT5A, NOTCH1, SOX9, GSK3B, HMGA2, TGFB2, TGFBR3, TRIM28, CUL7, HIF1A, FAM101B, HNRNPAB, FAM83D, LOXL2 |
GO:0001840 | BP | neural plate development | The process whose specific outcome is the progression of the neural plate over time, from its formation to the mature structure. The neural plate is a flat, thickened layer of ectodermal cells. The underlying dorsal mesoderm signals the ectodermal cells above it to elongate into columnar neural plate cells. The neural plate subsequently develops into the neural tube, which gives rise to the central nervous system. |
CTNNB1 |
GO:0001841 | BP | neural tube formation | The formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system. |
SOX4, STK4, MIB1 |
GO:0001843 | BP | neural tube closure | The last step in the formation of the neural tube, where the paired neural folds are brought together and fuse at the dorsal midline. |
ARID1A, PLXNB2, KDM6A, SPINT2, FZD6, COBL, TULP3, LRP6, BCL10, TGFB1, PFN1, RALA, MTHFD1, BMP4, SKI, PRKACA, SDC4, ADM, TSC2, LHX2, TGFB2, LMO4, RPS7, PTCH1, TMED2, STIL, TEAD2, TWIST1, MTHFD1L, PHACTR4, SHROOM3, GLMN, MED12, PRICKLE1, KIF20B, DLC1, IFT122, MKS1, CC2D2A, SUFU |
GO:0001844 | BP | protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | The process in which a protein is incorporated into a mitochondrial membrane as the initial phase of the mitochondrial membrane permeabilization that takes place in the apoptotic signaling pathway. |
BCL2L11, BAX, PMAIP1, BAD, MOAP1 |
GO:0001845 | BP | phagolysosome assembly | The process that results in the fusion of a phagosome, a vesicle formed by phagocytosis, with a lysosome. |
CORO1A |
GO:0001846 | MF | opsonin binding | Interacting selectively and non-covalently with an opsonin, such as a complement component or antibody, deposited on the surface of a bacteria, virus, immune complex, or other particulate material. |
ITGAV |
GO:0001847 | MF | opsonin receptor activity | Combining with an opsonin and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
CD14 |
GO:0001848 | MF | complement binding | Interacting selectively and non-covalently with any component or product of the complement cascade. |
CFB, C8G, C4A, C4B |
GO:0001849 | MF | complement component C1q binding | Interacting selectively and non-covalently with the C1q component of the classical complement cascade. |
CRP, APCS, C4A, PTX3, CALR, C1QBP, CD93 |
GO:0001850 | MF | complement component C3a binding | Interacting selectively and non-covalently with the C3a product of the complement cascade. |
PHB |
GO:0001851 | MF | complement component C3b binding | Interacting selectively and non-covalently with the C3b product of the complement cascade. |
CR1, PHB |
GO:0001855 | MF | complement component C4b binding | Interacting selectively and non-covalently with the C4b product of the classical complement cascade. |
MASP2, CR1 |
GO:0001856 | MF | complement component C5a binding | Interacting selectively and non-covalently with the C5a product of the complement cascade. |
C5AR1 |
GO:0001861 | MF | complement component C4b receptor activity | Combining with the C4b product of the classical complement cascade and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
CR1 |
GO:0001867 | BP | complement activation, lectin pathway | Any process involved in the activation of any of the steps of the lectin pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes. |
MASP2, KRT1, MBL2, FCN2 |
GO:0001869 | BP | negative regulation of complement activation, lectin pathway | Any process that stops, prevents, or reduces the rate of complement activation by the lectin pathway. |
A2M, SERPING1 |
GO:0001872 | MF | (1->3)-beta-D-glucan binding | Interacting selectively and non-covalently with (1->3)-beta-D-glucans. |
PTX3 |
GO:0001875 | MF | lipopolysaccharide receptor activity | Combining with a lipopolysaccharide and transmitting the signal across the cell membrane to initiate a change in cell activity. Lipopolysaccharides (LPS) are major components of the outer membrane of Gram-negative bacteria, making them prime targets for recognition by the immune system. |
TLR4, TLR2, PTAFR, SCARB1 |
GO:0001878 | BP | response to yeast | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a yeast species. |
ANG, APP, MPO, IL6, PTX3 |
GO:0001880 | BP | Mullerian duct regression | The process in which the Mullerian ducts, primordia of the oviducts, uterus and upper vagina, undergo regression in male embryos. |
AMH, BMPR1A, AMHR2, SMAD5 |
GO:0001881 | BP | receptor recycling | The process that results in the return of receptor molecules to an active state and an active cellular location after they have been stimulated by a ligand. An active state is when the receptor is ready to receive a signal. |
RAB11B, ALS2, EHD3, ARFGEF2 |
GO:0001882 | MF | nucleoside binding | Interacting selectively and non-covalently with a nucleoside, a compound consisting of a purine or pyrimidine nitrogenous base linked either to ribose or deoxyribose. |
ACTN4, PNP, POLA1 |
GO:0001883 | MF | purine nucleoside binding | Interacting selectively and non-covalently with a purine nucleoside, a compound consisting of a purine base linked either to ribose or deoxyribose. |
ADA, ADORA1 |
GO:0001885 | BP | endothelial cell development | The progression of an endothelial cell over time, from its formation to the mature structure. |
GPX1, VEZF1, CCM2 |
GO:0001886 | BP | endothelial cell morphogenesis | The change in form (cell shape and size) that occurs during the differentiation of an endothelial cell. |
MET, COL18A1, ID1, STC1, ARHGEF26, HEG1 |
GO:0001887 | BP | selenium compound metabolic process | The chemical reactions and pathways involving compounds that contain selenium, such as selenocysteine. |
SEPP1, TXNRD1, SCLY |
GO:0001889 | BP | liver development | The process whose specific outcome is the progression of the liver over time, from its formation to the mature structure. The liver is an exocrine gland which secretes bile and functions in metabolism of protein and carbohydrate and fat, synthesizes substances involved in the clotting of the blood, synthesizes vitamin A, detoxifies poisonous substances, stores glycogen, and breaks down worn-out erythrocytes. |
COBL, ALDH1A2, ADA, ASS1, KRAS, JUN, ASNS, QDPR, IGF2R, HGF, XBP1, SRD5A1, MPST, AK4, CAD, HMGCL, PIK3CA, NOTCH1, CEBPG, GFER, SMAD3, PKD1, HMGCS1, SP3, TGFBR3, RELA, PKD2, HNRNPD, HES1, ARID5B, AACS, LSR, PCSK9, RB1CC1, PROX1, GATA6, CITED2, CADM1, UPF2, SEC63 |
GO:0001890 | BP | placenta development | The process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
E2F8, ADA, ANG, DCN, HSP90AB1, HSD17B2, PPARG, CCNF, LEP, RPS6, NDP, MC2R, PTK2, ALKBH1, CUL7, MAPK14, PHLDA2, HTRA1, CITED1, RTCB, MAP3K4 |
GO:0001891 | CC | phagocytic cup | An invagination of the cell membrane formed by an actin dependent process during phagocytosis. Following internalization it is converted into a phagosome. |
MYO1G, PIP5K1C, TNF, ANXA1, LCP1, CORO1A, RAC1, RACK1, TRIP10, PEAR1, MEGF10, SYT11, CDC42SE2, BIN2, SNX5 |
GO:0001892 | BP | embryonic placenta development | The embryonically driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
EGFR, PDGFB, CEBPB, TFEB, ARNT, PKD1, HSF1, SP3, PKD2, HIF1A, EPAS1 |
GO:0001893 | BP | maternal placenta development | Maternally driven process whose specific outcome is the progression of the placenta over time, from its formation to the mature structure. The placenta is an organ of metabolic interchange between fetus and mother, partly of embryonic origin and partly of maternal origin. |
NR2F2, AKT1, BMPR2, TMED2, DAZAP1 |
GO:0001894 | BP | tissue homeostasis | A homeostatic process involved in the maintenance of an internal steady state within a defined tissue of an organism, including control of cellular proliferation and death and control of metabolic function. |
RB1, AKR1B1, CTGF, SOX9, GNAS, STK11, GNAS, ANKRD11, TP53INP2, NANOS1, P2RX4, BARD1 |
GO:0001895 | BP | retina homeostasis | A tissue homeostatic process involved in the maintenance of an internal equilibrium within the retina of the eye, including control of cellular proliferation and death and control of metabolic function. |
ALB, TF, KRT1, HSPB1, AZGP1, ACTB, LYZ, B2M, ACTG1, PRDX1, POTEE, BBS1, WDR36, BBS10, POC1B, PROL1 |
GO:0001909 | BP | leukocyte mediated cytotoxicity | The directed killing of a target cell by a leukocyte. |
STXBP2 |
GO:0001910 | BP | regulation of leukocyte mediated cytotoxicity | Any process that modulates the frequency, rate, or extent of leukocyte mediated cytotoxicity. |
ICAM1 |
GO:0001912 | BP | positive regulation of leukocyte mediated cytotoxicity | Any process that activates or increases the frequency, rate or extent of leukocyte mediated cytotoxicity. |
CCL2 |
GO:0001913 | BP | T cell mediated cytotoxicity | The directed killing of a target cell by a T cell through the release of granules containing cytotoxic mediators or through the engagement of death receptors. |
CTSH, CTSC, EMP2, MICB, MICA |
GO:0001915 | BP | negative regulation of T cell mediated cytotoxicity | Any process that stops, prevents, or reduces the rate of T cell mediated cytotoxicity. |
PTPRC, IL7R, LILRB1 |
GO:0001916 | BP | positive regulation of T cell mediated cytotoxicity | Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity. |
STX7, HLA-E, IL12A, IL12RB1, B2M, FADD |
GO:0001917 | CC | photoreceptor inner segment | The inner segment of a vertebrate photoreceptor containing mitochondria, ribosomes and membranes where opsin molecules are assembled and passed to be part of the outer segment discs. |
INHA, ENO2, MAK, PDC, GNB1, CROCC, DRAM2, PHLPP2, RDH11, GUCA1B |
GO:0001919 | BP | regulation of receptor recycling | Any process that modulates the frequency, rate, or extent of receptor recycling. |
LAMTOR1, TBC1D16 |
GO:0001920 | BP | negative regulation of receptor recycling | Any process that stops, prevents, or reduces the rate of receptor recycling. |
PCSK9, OPTN |
GO:0001921 | BP | positive regulation of receptor recycling | Any process that activates or increases the frequency, rate or extent of receptor recycling. |
RAB29, RAMP3, SNCA, EPS15, NSG1, ECE1, NSF, PSEN1, VAMP3, BVES, ARAP1 |
GO:0001922 | BP | B-1 B cell homeostasis | The process of regulating the proliferation and elimination of B cells of the B-1 subset such that the total number of B-1 B cells within a whole or part of an organism is stable over time in the absence of an outside stimulus. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity. |
TNFAIP3, HIF1A |
GO:0001927 | BP | exocyst assembly | The aggregation, arrangement and bonding together of various polypeptides into the exocyst complex. |
EXOC2 |
GO:0001928 | BP | regulation of exocyst assembly | Any process that modulates the frequency, rate or extent of exocyst assembly. |
RALB |
GO:0001931 | CC | uropod | A membrane projection with related cytoskeletal components at the trailing edge of a cell in the process of migrating or being activated, found on the opposite side of the cell from the leading edge or immunological synapse, respectively. |
PIP5K1B, PIP5K1C, FLOT1, EZR, MYH9, SELPLG |
GO:0001932 | BP | regulation of protein phosphorylation | Any process that modulates the frequency, rate or extent of addition of phosphate groups into an amino acid in a protein. |
PLXNB2, SOCS1, NDUFS4, TADA3, APOA1, FN1, LYN, STAT2, SESN2, PTK2, RAD51, CCDC88A, FLCN, FNIP1, PHIP, CELSR3, FNIP2, CORO1C |
GO:0001933 | BP | negative regulation of protein phosphorylation | Any process that stops, prevents or reduces the rate of addition of phosphate groups to amino acids within a protein. |
PLPP3, CTDSP2, CTDSPL, PARK2, LRP6, SLIT2, TGFB1, PRNP, LYN, CCNB1, IGFBP3, FBLN1, SNCA, XDH, PTEN, PRKDC, INSM1, TARDBP, ANGPT1, PID1, DNAJC10, MICAL1, ZBED3, MYADM, CHP1, CIB1, INPP5K, FAM129A, CTDSP1, PARD6A, IMPACT, PPARGC1A, RABGEF1, CORO1C |
GO:0001934 | BP | positive regulation of protein phosphorylation | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. |
CYR61, CDK2AP1, MUSK, AXIN1, HDAC3, TBX1, ROCK2, FLOT1, FGF19, EGFR, F2, C3, KRAS, TGFB1, IGF2, TNF, IL1B, ERBB2, NTRK1, ITGB3, INSR, CSF1R, ANXA2, RAP2A, RALB, BMP2, BMP4, MMP9, VEGFA, MT3, ACVR2A, MAPK3, ERP29, CCND2, CCND3, AKT1, AKT2, FLT4, OPRL1, SOX9, CSNK1D, EFNA5, RAC1, RACK1, ADAM17, DAB2, TEK, PLAUR, PTK2, STK4, SQSTM1, RIPK1, GAS6, ERBB4, ADIPOQ, NTRK2, BRAT1, IL34, KNDC1, MAVS, FLCN, FBXO18, RB1CC1, FNIP1, ITLN1, MYDGF, GPER1, CIB1, RARRES2, PINK1, FAM129A, AKTIP, PELI2, TNIK |
GO:0001935 | BP | endothelial cell proliferation | The multiplication or reproduction of endothelial cells, resulting in the expansion of a cell population. Endothelial cells are thin flattened cells which line the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium. |
ERN1, APOA1, HMOX1, XBP1, PIK3CB, MMP14, PRKX, TEK, DLG1, BMPR2, SCARB1, NOX5, THAP1, LOXL2 |
GO:0001936 | BP | regulation of endothelial cell proliferation | Any process that modulates the frequency, rate, or extent of endothelial cell proliferation. |
ALDH1A2, LEP |
GO:0001937 | BP | negative regulation of endothelial cell proliferation | Any process that stops, prevents, or reduces the rate or extent of endothelial cell proliferation. |
KRIT1, APOE, APOH, THBS1, SPARC, SCG2, GJA1, NR2F2, PTPRM, TGFBR1, XDH, CAV2, SYNJ2BP, CAV1, SULF1, ATOH8, RGCC, GHRL |
GO:0001938 | BP | positive regulation of endothelial cell proliferation | Any process that activates or increases the rate or extent of endothelial cell proliferation. |
NRP1, NRP2, PDCD6, PDGFB, LRG1, ANG, ITGB3, JUN, FGF2, WNT2, BMP2, BMP4, CCL2, SCG2, VEGFA, PRKCA, BMP6, NR4A1, HMGB2, ARNT, AKT1, THBS4, FLT4, TGFBR1, WNT5A, HTR2B, STAT5A, CXCL12, PGF, VEGFC, CAV2, CDH13, TEK, EGR3, SEMA5A, BMPR2, PRKD1, HIF1A, RICTOR, VASH2, AGGF1, PROX1, MYDGF, PRKD2, PDCL3, ZNF580 |
GO:0001939 | CC | female pronucleus | The pronucleus originating from the ovum that is being fertilized. |
SLC2A1, CCNA2, CBX1, RIF1 |
GO:0001940 | CC | male pronucleus | The pronucleus originating from the spermatozoa that was involved in fertilization. |
CCNA2, CBX1, RIF1 |
GO:0001941 | BP | postsynaptic membrane organization | A process which results in the assembly, arrangement of constituent parts, or disassembly of a postsynaptic membrane, the specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). |
CHRNB1 |
GO:0001942 | BP | hair follicle development | The process whose specific outcome is the progression of the hair follicle over time, from its formation to the mature structure. A hair follicle is a tube-like opening in the epidermis where the hair shaft develops and into which the sebaceous glands open. |
LDB2, FZD6, LGR5, DKK1, EGFR, PDGFA, INHBA, ACVR1B, SOX9, LHX2, TGFB2, RELA, SOS1, NSDHL, APCDD1, LGR4, TNFRSF19 |
GO:0001944 | BP | vasculature development | The process whose specific outcome is the progression of the vasculature over time, from its formation to the mature structure. The vasculature is an interconnected tubular multi-tissue structure that contains fluid that is actively transported around the organism. |
TCF21, ZFAND5, FLT4, PIK3CA, STK11, ANP32B, B9D1 |
GO:0001945 | BP | lymph vessel development | The process whose specific outcome is the progression of a lymph vessel over time, from its formation to the mature structure. |
TBX1, FLT4, SYK, EFNB2, FOXC1, HEG1 |
GO:0001946 | BP | lymphangiogenesis | Lymph vessel formation when new vessels emerge from the proliferation of pre-existing vessels. |
FLT4, ACVR2B, BMPR2, CCBE1, PDPN, PROX1 |
GO:0001947 | BP | heart looping | The tube morphogenesis process in which the primitive heart tube loops asymmetrically. This looping brings the primitive heart chambers into alignment preceding their future integration. Heart looping begins with dextral-looping and ends when the main regional divisions of the mature heart and primordium of the great arterial trunks become established preceeding septation. |
MICAL2, FOLR1, GJA1, TGFBR2, WNT5A, GATA4, NOTCH1, PSEN1, SMAD3, MEF2C, PKD2, TMED2, STIL, HIF1A, NPHP3, MIB1, CCDC103, BBS7, AHI1, SETDB2, SOX17, MKKS, NDRG4, SUFU |
GO:0001948 | MF | glycoprotein binding | Interacting selectively and non-covalently with a glycoprotein, a protein that contains covalently bound glycose (monosaccharide) residues. These also include proteoglycans. |
SDCBP, EGFR, PLAT, SERPINA1, LDLR, TGFB1, CD4, APOH, TFRC, VWF, ITGB2, FYN, HSP90AA1, THBS1, HSP90AB1, VIM, LGALS1, HSPA5, ITGAM, IGF2R, IDE, SDC1, RASA1, FLNA, AZGP1, ITGA3, CALR, CANX, BMPR1A, CSNK1D, B2M, VLDLR, CNTN1, OS9, SHB, EDEM1, FBXO17, BBC3, TFR2 |
GO:0001949 | BP | sebaceous gland cell differentiation | The process in which a relatively unspecialized epidermal cell acquires the specialized features of a sebaceous gland cell. |
FA2H |
GO:0001951 | BP | intestinal D-glucose absorption | Uptake of D-glucose into the blood by absorption from the small intestine. |
EZR, PLS1 |
GO:0001952 | BP | regulation of cell-matrix adhesion | Any process that modulates the frequency, rate or extent of attachment of a cell to the extracellular matrix. |
BCL2, PIK3CB, DDR1, MINK1 |
GO:0001953 | BP | negative regulation of cell-matrix adhesion | Any process that stops, prevents, or reduces the rate or extent of cell adhesion to the extracellular matrix. |
CASK, SEMA3E, THBS1, RASA1, PIK3R1, NF2, BCL6, POSTN |
GO:0001954 | BP | positive regulation of cell-matrix adhesion | Any process that activates or increases the rate or extent of cell adhesion to an extracellular matrix. |
CD36, VEGFC, GSK3B, EMP2, CDH13, CDK6, ILK, SFRP1, CIB1, PLEKHA2 |
GO:0001955 | BP | blood vessel maturation | A developmental process, independent of morphogenetic (shape) change, that is required for a blood vessel to attain its fully functional state. |
RECK, MMP2, S1PR1, CDH5, DDIT3 |
GO:0001956 | BP | positive regulation of neurotransmitter secretion | Any process that activates or increases the frequency, rate or extent of the regulated release of a neurotransmitter. |
SNCA, GPER1 |
GO:0001957 | BP | intramembranous ossification | Direct ossification that occurs within mesenchyme or an accumulation of relatively unspecialized cells. |
FGF18, COL1A1, MMP2, CTSK, MN1 |
GO:0001958 | BP | endochondral ossification | Replacement ossification wherein bone tissue replaces cartilage. |
FGF18, COL1A1, ALPL, BMP4, BMP6, MMP14, MMP16, DLX5, GNAS, TEK, COL10A1, MEF2C, RUNX2, MEF2D, GNAS, COL13A1, CSGALNACT1 |
GO:0001959 | BP | regulation of cytokine-mediated signaling pathway | Any process that modulates the frequency, rate or extent of the cytokine mediated signaling pathway. |
IRAK2, CD24, IRAK1 |
GO:0001960 | BP | negative regulation of cytokine-mediated signaling pathway | Any process that stops, prevents, or reduces the frequency, rate or extent of the cytokine mediated signaling pathway. |
PTPRC, CAV1, SIGIRR, IRAK3 |
GO:0001961 | BP | positive regulation of cytokine-mediated signaling pathway | Any process that activates or increases the frequency, rate or extent of a cytokine mediated signaling pathway. |
RIPK2, CD74, GAS6 |
GO:0001963 | BP | synaptic transmission, dopaminergic | The process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine. |
TH, DRD2, CDK5, RASD2 |
GO:0001964 | BP | startle response | An action or movement due to the application of a sudden unexpected stimulus. |
PARK2, PENK, GLRB, NRG1, KCNA1, GRIN2A |
GO:0001965 | MF | G-protein alpha-subunit binding | Interacting selectively and non-covalently with a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide. |
RGS10, IGF2R, F2R, RGS2, HTR2B, RGS4, F2RL1, GPSM2, NUCB1 |
GO:0001966 | BP | thigmotaxis | The directed movement of a motile cell or organism in response to touch. |
ID2 |
GO:0001967 | BP | suckling behavior | Specific behavior of a newborn or infant mammal that results in the derivation of nourishment from the breast. |
GLS, APP, OXTR, UBR3, DERL2, DACH1 |
GO:0001968 | MF | fibronectin binding | Interacting selectively and non-covalently with a fibronectin, a group of related adhesive glycoproteins of high molecular weight found on the surface of animal cells, connective tissue matrices, and in extracellular fluids. |
ITGB3, ITGB1, ITGAV, CTSL, THBS1, VEGFA, IGFBP3, FBLN1, IGFBP5, CTSS, ITGA3, CTGF, SDC4, CTSK, HSD17B12, CCDC80, PLEKHA2 |
GO:0001970 | BP | positive regulation of activation of membrane attack complex | Any process that activates, maintains or increases the frequency, rate or extent of the activation of the membrane attack complex components of the complement cascade. |
C3, C6 |
GO:0001972 | MF | retinoic acid binding | Interacting selectively and non-covalently with retinoic acid, 3,7-dimethyl-9-(2,6,-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid. |
CYP26A1, SERPINA5, IGF2R, NR2F2, CYP26B1 |
GO:0001973 | BP | adenosine receptor signaling pathway | The series of molecular signals generated as a consequence of a receptor binding to extracellular adenosine and transmitting the signal to a heterotrimeric G-protein complex to initiate a change in cell activity. |
GNAI2, ADORA2B, ADORA1 |
GO:0001974 | BP | blood vessel remodeling | The reorganization or renovation of existing blood vessels. |
HOXA3, NOL3, AGT, ACE, LIF, BGN, TGM2, NOS3, AGTR2, TGFB2, JAG1, MDM2, MEF2C, BAX, FOXC1, ACVR2B, BMPR2, EPAS1, SEMA3C, RSPO3, DLL4, CHD7 |
GO:0001975 | BP | response to amphetamine | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an amphetamine stimulus. Amphetamines consist of a group of compounds related to alpha-methylphenethylamine. |
ICAM1, TH, DRD2, OXTR, NR4A2, RANBP2, CALM2, SLC18A2, PPP3CA, GRIN2A, HDAC1, DPYSL2, HDAC2, HDAC9 |
GO:0001976 | BP | neurological system process involved in regulation of systemic arterial blood pressure | The regulation of blood pressure mediated by detection of stimuli and a neurological response. |
DRD2 |
GO:0001980 | BP | regulation of systemic arterial blood pressure by ischemic conditions | The process that modulates blood pressure by the detection of carbon dioxide levels in the brain stem. Increased levels activate the sympathetic vasoconstrictor mechanism increasing the force with which blood flows through the circulatory system. |
TNNI3 |
GO:0001985 | BP | negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressure | Any process that stops, prevents, or reduces the frequency, rate or extent of heart contraction as a result of the baroreceptor response to increased blood pressure. |
ADRA1A |
GO:0001988 | BP | positive regulation of heart rate involved in baroreceptor response to decreased systemic arterial blood pressure | Any process that activates, maintains or increases the frequency, rate or extent of heart contraction as a result of the baroreceptor response to decreased blood pressure. |
CHRNA7 |
GO:0001991 | BP | regulation of systemic arterial blood pressure by circulatory renin-angiotensin | The process in which angiotensinogen metabolites in the bloodstream modulate the force with which blood passes through the circulatory system. The process begins when renin is released and cleaves angiotensinogen. |
AGTR2 |
GO:0001992 | BP | regulation of systemic arterial blood pressure by vasopressin | The regulation of blood pressure mediated by the signaling molecule vasopressin. Vasopressin is produced in the hypothalamus, and affects vasoconstriction, and renal water transport. |
AVPR2, OXTR |